TRK fusion proteins are an oncogenic driver across multiple tumors in adults and children1,2
- A tumor’s underlying genomic profile has become increasingly important in oncology. Genomic alterations, such as NTRK gene fusions, are an ongoing area of focus2-5
- In TRK fusion cancer, the NTRK gene fuses with an unrelated gene, causing overexpression of the TRK protein2,3,6
- TRK fusion cancer, while rare, occurs in a broad range of tumor types with varying prevalence across both pediatric and adult patients.2 The only way to discover NTRK gene fusion is to properly test for it7
NTRK, neurotrophic tyrosine receptor kinase; TRK, tropomyosin receptor kinase.
References: 1. Okimoto RA, Bivona TG. Tracking down response and resistance to TRK inhibitors. Cancer Discov. 2016;6(1):14-16. 2. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5(1):25-34. 3. Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1(2):e000023. 4. Gower A, Wang Y, Giaccone G. Oncogenic drivers, targeting therapies, and acquired resistance in non-small-cell lung cancer. J Mol Med. 2014;92(7):697-707. 5. Yoshihara K, Wang Q, Torres-Garcia W, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34(37):4845-4854. 6. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129. doi:10.1186/s13073-015-0252-1. 7. Hechtman JF, Benayed R, Hyman DM, et al. Pan-trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41(11):1547-1551.
© 2018 Bayer and Loxo Oncology, Inc. All rights reserved. Bayer and the Bayer Cross are registered trademarks of Bayer.